Search

Author/Creator Besemer, B.

1. P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1. (23rd June 2022)

Authors:
Popat, R.; Moreau, P.; Usmani, S. Z.; Garfall, A.; Mateos, M.-V.; San-Miguel, J. F.; Oriol, A.; Nooka, A. K.; Rosinol, L.; Chari, A.; Karlin, L.; Krishnan, A.; Bahlis, N.; Martin, T.; Besemer, B.; Martínez-López, J.; Delforge, M.; Fastenau, J.; Gries, K. S.; van de Donk, N. W.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
812
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL. (23rd June 2022)

Authors:
Leypoldt, L.; Gavriatopoulou, M.; Besemer, B.; Salwender, H.; Raab, M.-S.; Nogai, A.; Khandanpour, C.; Runde, V.; Zago, M.; Martus, P.; Goldschmidt, H.; Bokemeyer, C.; Dimopoulos, M.; Weisel, K.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
816
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL. (23rd June 2022)

Authors:
Mai, E. K.; Bertsch, U.; Fenk, R.; Tichy, D.; Besemer, B.; Dürig, J.; Schroers, R.; von Metzler, I.; Hänel, M.; Mann, C.; Asemissen, A. M.; Heilmeier, B.; Nievergall, E.; Huhn, S.; Kriegsmann, K.; Weinhold, N.; Luntz, S.; Holderrried, T. A. W.; Trautmann-Grill, K.; Gezer, D.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
820
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA. (23rd June 2022)

Authors:
Usmani, S. Z.; Mielnik, M.; Koh, Y.; Alonso Alonso, A.; Leleu, X.; Quach, H.; Min, C.-K.; Janowski, W.; Abdallah, A.-O.; Garg, M.; Sandhu, I.; Ocio San Miguel, E. M.; Oriol, A.; Rodriquez-Otero, P.; Ramasamy, K.; Weisel, K.; Besemer, B.; Cavo, M.; Zhou, X. L.; Kaisermann, M. C.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
832
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P958: REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSES FROM THE LOCOMMOTION STUDY. (23rd June 2022)

Authors:
Einsele, H.; Moreau, P.; De Stefano, V.; Dytfeld, D.; Angelucci, E.; Benjamin, R.; Goldschmidt, H.; van de Donk, N. W.; Besemer, B.; Scheid, C.; Vij, R.; '. Groen-Damen, E. I.; Semerjian, M.; Strulev, V.; Schecter, J. M.; Roccia, T.; Nesheiwat, T.; Wapenaar, R.; Weisel, K.; Mateos, M.-V.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
848
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS. (23rd June 2022)

Authors:
Touzeau, C.; Krishnan, A.; Moreau, P.; Perrot, A.; Usmani, S. Z.; Manier, S.; Cavo, M.; Martinez-Chamorro, C.; Nooka, A.; Martin, T.; Karlin, L.; Leleu, X.; Bahlis, N.; Besemer, B.; Pei, L.; Verona, R.; Girgis, S.; Uhlar, C.; Kobos, R.; Garfall, A.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
85
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search